Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-??, KDR, and CSF-1R, respectively.
More Information Supplier PageLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-??, KDR, and CSF-1R, respectively.
More Information Supplier PageLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-??, KDR, and CSF-1R, respectively.
More Information Supplier PageLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-??, KDR, and CSF-1R, respectively.
More Information Supplier PageLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-??, KDR, and CSF-1R, respectively.
More Information Supplier PageABT-751 is an antimitotic agent, inhibits microtubule polymerization, binds to β-tubulin on the colchine site; blocks cell cycle at G2M phase and induces apoptosis.
More Information Supplier PageABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
More Information Supplier PageABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
More Information Supplier PageAcarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes.
More Information Supplier PageAcadesine is a selective activator of AMPK in both hepatocytes and adipocytes.
More Information Supplier Page
